ReviewInternational journal of nanomedicine2025
Small Extracellular Vesicles: Unraveling Their Roles in Ovarian Cancer Progression and Tapping Into Clinical Application Potential.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tuning Secretomes for Regenerative Medicine.Biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among gynecologic malignancies, ovarian cancer (OC) stands out as a highly aggressive disease with the highest mortality rate and the poorest prognosis. At the beginning stage, it demonstrates high sensitivity to platinum-based chemotherapy. Nevertheless, most patients will encounter recurrence following the initial surgery and chemotherapy. Small extracellular vesicles (sEVs), characterized by a "cup-shaped" morphology and with a diameter of 40 to 160 nm, encompass diverse biologically active substances including nucleic acids (such as DNA, mRNA, microRNA (miRNA), and other non-coding RNAs (ncRNAs)), as well as oncogenic proteins, lipids, and metabolites, which play a crucial role as mediators of intercellular communication. Increasing evidence shows that sEVs promote various cancers' progression (including OC) via transporting molecular cargoes to target cells or organs. It is worth mentioning that existing literature often focuses on sEVs from a single cell type and lacks a comprehensive review of multiple cell sources. In this review, we summarize the biological functions of sEVs derived from different cell types in OC, including regulating cell proliferation, promoting metastasis, mediating drug resistance, inducing angiogenesis, facilitating immune escape, and maintaining stemness. Meanwhile, we focus on exploring the clinical value of sEVs as biomarkers for the diagnosis and prognosis of OC, as well as their application potential in translational medicine fields related to cancer vaccine development, targeted drug delivery, and precision tumor-targeted therapy. Additionally, we analyze the major challenges currently faced in sEV-based OC treatment research and propose potential strategies to overcome these limitations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.